JAKARTA - The development of domestically produced vaccines continues to show an important role in supporting public health resilience.
Various efforts to strengthen local vaccine research, production, and innovation are considered to increase national independence while expanding public access to quality health products.
In this context, a number of national biopharmaceutical industry players have recorded achievements that reflect their contributions to the Indonesian health ecosystem, as is the case with PT Etana Biotechnologies Indonesia (Etana) which closed 2025 with several achievements in the field of biopharmaceutical product development.
At the end of this year, this biopharmaceutical manufacturer received the National Children's Work Award from the Ministry of Health of the Republic of Indonesia for innovation in the field of vaccines.
In addition, the company also obtained a Distribution Permit (NIE) from the Food and Drug Supervisory Agency (BPOM) for one of the oncology products to be marketed in Indonesia.
Director of the Etana Anti-Infectious Business Unit, Indra Lamora, said that this achievement was part of a long-term process in building a biopharmaceutical industry based on innovation and compliance with regulations.
"This achievement reflects Etana's commitment to developing sustainable biopharmaceutical innovations, while maintaining compliance with regulations and a real contribution to the national health system. In the future, Etana will continue to strengthen the development of innovation in the field of vaccines and disease therapies," said Indra.
The National Children's Work Award was given to Etana for his contribution to the development and production of mRNA vaccines and PCV-13 vaccines in the country.
In addition, the company also received appreciation for the development of a tuberculosis (TB) vaccine candidate which is currently undergoing phase 1 clinical trials, in accordance with the approval and supervision of the relevant authorities.
This achievement reflects the efforts to strengthen the capacity of research and development of biopharmaceutical products in Indonesia, as well as support for the sustainability of innovation in the field of health.
Outside of vaccine development, Etana also recorded progress in terms of expanding the product portfolio, with the marketing approval for the oncology product Neratinib Maleate Tablets with the trade name Hernera®.
This product is one of the drugs that obtained the BPOM Distribution Permit Number through the registration mechanism of new drugs in accordance with applicable regulations.
In Indonesia, the product is approved for certain indications as stated in the product information and BPOM approval, including its use in the treatment of HER2-positive breast cancer, after evaluating the aspects of quality, safety, and efficacy.
This approval is expected to add to the choice of therapy in the field of oncology in Indonesia, while still referring to the use of appropriate medical indications and applicable regulations. In general, achievements in the fields of innovation and regulation are in line with the government's efforts to strengthen the independence of the national pharmaceutical industry and the resilience of the health system.
The company stated that it would continue to carry out all product development, production, and distribution processes in accordance with laws and regulations as well as good corporate governance principles.
"Closing the year with these various achievements, Etana sees the coming year as a continuation phase to strengthen the capacity of innovation, collaboration, and an active role in supporting the development of Indonesian health," concluded Indra.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
